Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of human beta-defensin-1 in preparation of drugs for treating or preventing hepatitis B virus infection

A technology of hepatitis B virus and hepatitis B, applied in antiviral agents, pharmaceutical formulas, medical preparations containing active ingredients, etc., can solve problems such as unclear specific mechanisms

Active Publication Date: 2015-11-11
广东龙帆生物科技有限公司
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The only research on the effect of β-defensin-1 on viruses is its anti-HIV activity, and its specific mechanism is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of human beta-defensin-1 in preparation of drugs for treating or preventing hepatitis B virus infection
  • Use of human beta-defensin-1 in preparation of drugs for treating or preventing hepatitis B virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Over-expression experimental evaluation of β-defense-1 anti-HBV activity.

[0028] A person β-defense-1 in the application of the treatment of hepatitis B virus infection drugs is:

[0029] 1. Experimental materials:

[0030] 1.1 Cells, plasmids:

[0031] Hepg2 cells (from ATCC) and PHBV1.3 plasmid.Taking the total mRNA extracted from the HUH7 cell as the template, first use the CDNA as a template through the reverse transcription PCR amplification, and then use the special primer to expand the full HBD1 gene fragment. The primer sequence is as follows:

[0032] HBD1CDSFORWARD: 5’-CGCGAATTCGAGAGACTCTACTACTCTC-3 '

[0033] hbd1cdsreverse: 5’-tatCTCGAGCAGCAGCACACTTGCCTTC-3 '

[0034] The HBD1 gene cloning is cut to the carrier PCAGGS (purchased from addgne) through specific restricted intrase enzymes (ECORI and XHOI) enzymes, and the PCAGGS-HBD1 expresses plasmid and sequencies identification.

[0035] 1.2 Reagent:

[0036] DMEM Cultivation Basic purchases are from ...

Embodiment 2

[0043] Example 2: The anti-HBV activity of β-defense-1 is evaluated by interference experiments.

[0044] A person β-defense-1 in the application of the treatment of hepatitis B virus infection drugs is:

[0045] 1. Experimental materials:

[0046] Interference RNA package is purchased from Guangzhou Ruibo Company.

[0047] 2. Experimental methods are the same as Example 1.

[0048] 3. Experimental results:

[0049] First detect the interference effect of interference RNA, such as figure 1 C shows that the inhibitory efficiency is about 80%.like figure 1 D. The expression of HBEAG and HBSAG in interference in HBD1 shown in 1E and HBSAG and the level of HBV replication of the intermediate nucleus shell -related DNA in the cell, indicating that HBD1 suppresss HBV replication, and HBD1 has anti -HBV activity.

[0050] Other steps are the same as Example 1.

[0051] Experimental results of the above embodiments 1 and Example 2 show that HBD1 has a good role in suppressing the replicat...

Embodiment 3

[0052] Example 3MTS detection PCAGGS-HBD1 effect on cell survival rate

[0053] like figure 2 The PCAGGS-HBD1 plasmid of the corresponding amount shown in transfection is used to HEPG2 cells, and PCAGGS is used as a control. After 48 hours after transfectionHepg2 cell survival rate has no effect.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a use of human beta-defensin-1 in preparation of drugs for treating or preventing hepatitis B virus infection. Through cotransfection of beta-defensin-1 overexpression plasmids or small interfering RNAs targeting beta-defensin-1 and HBV 1.3 ploid plasmids into liver cells, beta-defensin-1-caused influence on hepatitis B virus replication is researched, and surface antigen and e antigen secreted by viruses and an intracellular virus nucleocapsid-related DNA level are detected, and the detection result shows that replication of hepatitis B viruses in liver cells are inhibited by beta-defensin-1. Beta-defensin-1 can influence HBV activity or influence HBV infection or replication after infection. Through individual use or combination with other anti-HBV drugs, beta-defensin-1 can produce important effects in prevention or treatment on hepatitis B virus infection. Human beta-defensin-1 is an anti-microbe polypeptide constitutively expressed in the human body and has no toxic and side effect on the human body at a physiological concentration.

Description

Technical field [0001] The present invention involves a new purpose of a human β-defense-1 (β-Defensin-1 (HBD1), which involves a person β-defensein-1 (HBD1).Hepatitisbvirus (HBV) application in drugs. Background technique [0002] Hepatitisbvirus (HBV) infection is one of the main factors that cause liver cancer, which seriously threatens human life and health.my country is a high incidence area for hepatitis B virus infection. There are about 120 million patients with chronic hepatitis B, and about 300,000 people die from hepatitis B caused by chronic hepatitis B each year.HBV belongs to the Department of liver -only DNA virus, and the genome is part of the dual -chain ring -shaped DNA.The core particles of HBV are 28nm, which is 20 mask. The virus shell consists of core protein HBC.The surface of the nucleus shell has a envelope, and the envelope contains three surface antigen Pres1, PRES2 and HBSAG.Infectious virus particles are also called Dane particles with a diameter of 4...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61P31/20
Inventor 吴建国邬开朗谢雪萍陈俊波谭秋萍刘芳
Owner 广东龙帆生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com